BCDA · NASDAQ
BioCardia (BCDA) Stock Price & Fundamentals
BioCardia (BCDA) closed at $245.52 on Oct 9, 2026, down 0.20% from the previous close of $246.01.
Share price, past year
1Y −2.29%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $245.52 |
| Sep 30, 2026 | $244.34 |
| Aug 31, 2026 | $250.02 |
| Jul 31, 2026 | $244.84 |
| Jun 30, 2026 | $254.02 |
| May 29, 2026 | $258.02 |
| Apr 30, 2026 | $261.17 |
| Mar 31, 2026 | $262.21 |
| Feb 27, 2026 | $245.07 |
| Jan 30, 2026 | $231.07 |
| Dec 31, 2025 | $238.53 |
| Nov 28, 2025 | $241.71 |
| Oct 31, 2025 | $242.84 |
Key statistics
- Market cap
- $3.68B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- $0.00
- Net income (TTM)
- −$7.34M
- Shares outstanding
- 15M
- Dividend yield
- —
- 52-week range
- $230.21 – $267.58
BioCardia's market cap is $3.68B, based on a share price of $245.52 and 15M shares outstanding as of Jun 30, 2026.
Financials
BioCardia reported revenue of $0.00 for fiscal 2025, down 100.00% from fiscal 2024.
BioCardia reported a net loss of $8.23M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $0.00 | −100.0% | −$8.23M | — | — | −$7.44M |
| FY2024ended Dec 31, 2024 | $58.00K | −87.8% | −$7.95M | −13,700.0% | — | −$7.89M |
| FY2023ended Dec 31, 2023 | $477.00K | −64.7% | −$11.57M | −2,425.8% | — | −$9.99M |
| FY2022ended Dec 31, 2022 | $1.35M | +33.2% | −$11.91M | −880.7% | — | −$10.63M |
| FY2021ended Dec 31, 2021 | $1.02M | +600.0% | −$12.62M | −1,243.7% | — | −$10.48M |
| FY2020ended Dec 31, 2020 | $145.00K | −79.6% | −$15.00M | −10,347.6% | — | −$12.39M |
| FY2019ended Dec 31, 2019 | $710.00K | +13.6% | −$14.71M | −2,071.7% | — | −$9.59M |
| FY2018ended Dec 31, 2018 | $625.00K | +30.5% | −$13.99M | −2,237.9% | — | −$11.14M |
| FY2017ended Dec 31, 2017 | $479.00K | −16.8% | −$12.31M | −2,569.5% | — | −$8.81M |
| FY2016ended Dec 31, 2016 | $576.00K | — | −$10.31M | −1,789.9% | — | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q4 FY2025ended Dec 31, 2025 | $0.00 | −$1.98M | — |
| Q3 FY2025ended Sep 30, 2025 | $0.00 | −$1.48M | — |
| Q2 FY2025ended Jun 30, 2025 | $0.00 | −$2.05M | −$0.40 |
| Q1 FY2025ended Mar 31, 2025 | $0.00 | −$2.71M | −$0.59 |
| Q4 FY2024ended Dec 31, 2024 | $0.00 | −$2.30M | — |
| Q3 FY2024ended Sep 30, 2024 | $0.00 | −$1.74M | — |
| Q2 FY2024ended Jun 30, 2024 | $3.00K | — | — |
| Q1 FY2024ended Mar 31, 2024 | $55.00K | — | — |
Company profile
- Name
- BioCardia, Inc.
- Ticker
- BCDA
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 320 Soquel Way, Sunnyvale, CA 94085
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0000925741
Recent SEC filings
- Oct 7, 2026
- Oct 1, 2026
- Sep 23, 2026
- Sep 21, 2026
- Sep 10, 2026
- Aug 24, 2026
- Aug 21, 2026
- Aug 12, 2026
Frequently asked questions
What is BioCardia's stock price?
BioCardia (BCDA) closed at $245.52 on Oct 9, 2026, down 0.20% from the previous close of $246.01.
What is BioCardia's market cap?
BioCardia's market cap is $3.68B, based on a share price of $245.52 and 15M shares outstanding as of Jun 30, 2026.
How much revenue does BioCardia make?
BioCardia reported revenue of $0.00 for fiscal 2025, down 100.00% from fiscal 2024.
Does BioCardia pay a dividend?
BioCardia's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from BioCardia, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures